BLOOD THERAPY LTD 10500137 2024-12-01 2025-11-30 2025-11-30 WeFile 1.0 2026-08-25 General trading false 1 0 0 0 8577 100 0 0 0 7272 100 0 0 0 0 10500137 2024-12-01 2025-11-30 10500137 2025-11-30 10500137 uk-gaap:AfterOneYear 2025-11-30 10500137 2024-12-01 10500137 uk-bus:Director1 2024-12-01 2025-11-30 10500137 uk-bus:Micro-entities 2024-12-01 2025-11-30 10500137 uk-bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 10500137 uk-bus:FullAccounts 2024-12-01 2025-11-30 10500137 uk-bus:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 10500137 2023-12-01 2024-11-30 10500137 2024-11-30 10500137 uk-gaap:AfterOneYear 2024-11-30 iso4217:GBP xbrli:pure
BLOOD THERAPY LTD
Company Registration Number
10500137
(England and Wales)

Unaudited Micro-Entity Accounts
For the Year Ended 30 November 2025

Prepared in accordance with the micro-entity provisions
of the Companies Act 2006 and FRS 105
BLOOD THERAPY LTD

Contents

Profit and Loss Account3
Balance Sheet4
Statement of Compliance5
Notes to the Financial Statements6–8
BLOOD THERAPY LTD

Profit and Loss Account

For the Year Ended 30 November 2025

2025
£
2024
£
Turnover50005300
Cost of raw materials and consumables00
Staff costs00
Other charges(5194)(5324)
Other operating income00
Profit before taxation (194) (24)
Tax on profit 0 0
Profit for the financial year (194) (24)
BLOOD THERAPY LTD

Balance Sheet

As at 30 November 2025

2025
£
2024
£
Current assets 8577 7272
Creditors: amounts falling due within one year (13896) (12397)
Net current assets (liabilities) (5319) (5125)
Total assets less current liabilities (5319) (5125)
Total net assets (liabilities) (5319) (5125)
Capital and reserves (5319) (5125)
BLOOD THERAPY LTD

Balance Sheet Continued

For the year ending 30 November 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

The accounts were approved by the Board of Directors and authorised for issue on 25 August 2026.

Samir Zebari
Director
BLOOD THERAPY LTD

Notes to the Financial Statements

For the Year Ended 30 November 2025

1. Accounting Policies

Turnover

Turnover is recognised when goods are delivered or services are provided.

Taxation

Corporation tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Debtors

Debtors are recognised at the settlement amount due.

Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments.

Creditors

Creditors are recognised when there is an obligation at the balance sheet date as a result of a past event.

BLOOD THERAPY LTD

Notes to the Financial Statements (continued)

2. Basis of Preparation

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime.

BLOOD THERAPY LTD

Notes to the Financial Statements (continued)

3. Employee Information

The average number of employees during the year was: 1